

Info Sheet for Technical description

No.0021

Organization

* Mandatory fields

Name of Organization*	Human Life CORD Japan Inc.	
Address, City, States, Zip, Country*	1-9-10, Nihonbashi-horidomecho, Chuo-ku, Tokyo, 103-0012, Japan	
URL	https://humanlifecord.com/en/	
Brief Descriptions of Organization* (Approx. 100 words)	Human Life CORD Japan Inc. (HLC), founded in April 2017 and based in Tokyo, is a clinical-stage regenerative medicine startup specializing in developing and manufacturing human umbilical cord-derived mesenchymal stromal cells (UC-MSCs) to tackle with rare/intractable, age-related diseases, etc. Through patented technologies developed with the Institute of Medical Science, University of Tokyo (IMSUT), HLC is advancing clinical and preclinical research to develop pioneering cell therapies with UC-MSCs in NIPCs, sarcopenia and some autoimmune diseases. With strategic manufacturing collaboration with New York Blood Center Enterprises, HLC aims to establish a highly reproducible, scalable and sustainable platform, making advanced cell therapies more accessible worldwide.	
Contact address	Name*	Akihito Nakata, Ph.D.
	Department* / Position	Executive Officer, Chief Strategy Officer, Corporate Strategy & Business Development
	E-mail* / TEL	anakata20@humanlifecord.com

What kind of technology do you want to offer? *

- ☒ **A.** Clinical Development Pipelines → Please see **Sheet [A]**
- ☐ **B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc. → Please see **Sheet [B]**
- ☒ **C.** Platform Technologies(*) that are not included in the above (Group B) → Please see **Sheet [C]**
- * Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

If you agree to the following, please check "Yes" below. *

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

☒ Yes

Do you have any collaborations/partnerships with pharmaceutical companies?

☒ Yes

☐ No

If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- ☐ Angel / Seed (including AMED/JST grants)
- ☐ Series A
- ☐ Series B
- ☒ Series C
- ☐ Series D or further advanced stages

Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? *

Options*	Comments
☒ Yes	Human Life CORD Japan Inc. is actively seeking for global partnering opportunities. We would be grateful if FIRM would support us in accelerating our partnering activities in a proactive manner. We can dispatch our presentation materials to FIRM.
☐ No	

Filled in by*

Date*

Akihito Nakata, Ph.D.

8-Aug-25

Sheet [A] Clinical Development Pipelines**Info Sheet for Technical overview**

No. A-0021

* Mandatoty fields

Title***Clinical and non-clinical development of pioneering cell therapies with human umbilical cord-derived mesenchymal stromal cells (UC-MSCs)****Development Phase***

- | | | |
|--|---|---|
| ☒ Basic Research | ☐ Drug Discovery | ☒ Pre-Clinical |
| ☒ Clinical Trial (Phase I) | ☒ Clinical Trial (Phase II) | ☐ Clinical Trial (Phase III) |
| ☐ Review | ☐ Others | |

Disease Area*

- | | | |
|---|---|--|
| ☐ Cancer | ☐ Central nervous system | ☐ Ophthalmology |
| ☒ Musculoskeletal | ☐ Endocrine / Metabolism | ☐ Cardiovascular |
| ☐ Urogenital | ☐ Digestive organ | ☐ Blood |
| ☐ Infection | ☐ Dermatology | ☒ Immunity |
| ☐ Otolaryngology | ☒ Respiratory | ☐ Others |

Description*

Human Life CORD Japan Inc has been advancing clinical and non-clinical research to develop pioneering cell therapies with UC-MSCs to tackle with rare and intractable diseases, age-related diseases, etc. as follows:

<Post-transplant complications>

- Indication: Non-infectious pulmonary complications after hematopoietic stem cell transplantation (NIPCs)
- Development stage: Phase II completed (Phase III in preparation)
- Study location: Japan

<Age-related diseases>

- Indication: Sarcopenia
- Development stage: Clinical observational study in progress
- Study locatoin: Brazil

<Respiratory diseases >

- Indication: COVID-19 ARDS
- Development stage: Phase I completed
- Study locatoin: Japan

<Neonatal respiratory diseases >

- Indication: Chronic lung disease (Bronchopulmonary dysplasia)
- Development stage: Clinical trial in preparation
- Study location: TBD

Filled in by*

Akihito Nakata, Ph.D.

Date*

8-Aug-25